BD Injects €3.5m into Irish Facility

Related tags Insulin

BD Injects €3.5m into Irish Facility
BD has invested €3.5m ($4.5m) at a syringe manufacturing facility in Ireland, creating 28 new jobs.

The €3.5m has been invested into new equipment to manufacture insulin pen needles, lancet blood sampling devices and BD’s Posiflush syringes - a prefilled saline and heparin lock flush hypodermic - at Becton, Dickinson and Company's (BD) facility in Drogheda, County Louth.

“This investment in Drogheda is part of the Company’s investment strategy for Ireland, which has also seen more than €34 million invested in our other plant in Dun Laoghaire, Co Dublin,” ​said Cormac Reynolds, Director of Diabetes Care Manufacturing for BD in Ireland.

CEO of the Industrial Development Authority (IDA) Ireland, Barry O’Leary, welcomed the news, adding: “Continuous innovation by companies is vital in order to stay competitive – what BD has done here in Drogheda is a prime example of this.”

Related topics Contract Manufacturing & Logistics

Related news

Show more